



1Q FY2010

(Fiscal Year Ending March 31, 2011)

Financial Results Presentation

July 30, 2010

Eisai Co., Ltd.



Safe Harbor Statement




- Materials and information provided during this presentation may contain so-called “forward-looking statements.” These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.
- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; regulatory agency’s examination period, obtaining regulatory approvals; domestic and foreign healthcare reforms; trends toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
- Also, for products that are approved, there are manufacturing and market regulatory

Variation Factors for 1Q FY2010 Net Sales by Segment



(Billion Yen)




Sales of Major Products - Aricept -




(Billion Yen, %)

	April – June 2009	April – June 2010	
	Results	Results	YOY
Japan	23.4	25.3	108
U.S. [\$ million]	42.7 [438]	50.2 [545]	118 [124]
Europe	7.2	5.8	81
Asia	1.6	1.7	108
Total	74.8	82.9	111



Sales by Segment






	April - June 2009			April - June 2010			
	Results	%	% on Sales	Results	%	% on Sales	YOY
Japan Pharmaceuticals Business	34.4	52.6	42.1	36.8	52.1	42.7	107
U.S. Pharmaceuticals Business [\$ million]	22.1 [227]	33.9	26.7	26.5 [288]	37.5	29.9	120 [127]
Europe Pharmaceuticals Business	2.0	3.1	16.2	1.3	1.8	11.5	64
Asia Pharmaceuticals Business	2.1	3.2	28.0	2.1	3.0	23.9	100
New Markets Pharmaceuticals Business	(0.0)	(0.0)	-	(0.1)	(0.1)	-	-
Reporting Segment Total	60.6	92.7	32.8	66.6	94.2	34.2	110
Others	4.7	7.3	46.9	4.1	5.8	42.5	86
R&D expenses & Non-allocated SG&A expenses	(41.1)			(37.9)			
Operating Profit	24.1		12.4	32.8		16.0	136



















HALAVEN (eribulin mesylate)














 : Major product in franchise



*Submission by partner

 Aricept patch* Alzheimer's disease (AD)  eszopiclone insomnia			
 Dacogen AML  DC-Bead hepatocellular carcinoma			
 HUMIRA* juvenile rheumatoid arthritis			

Forecast for 1H FY2010 Consolidated Financial Results (no change from the disclosure in May 2010)



(Billion Yen, %)

	April – September 2009		April – September 2010		
	Results	%	Forecast	%	YOY
Net Sales	395.0	100.0	416.0	100.0	105
Operating Income	49.1	12.4	56.0	13.5	114
Ordinary Income	45.2	11.4	52.5	12.6	116
Net Income	30.9	7.8	34.5	8.3	112
Dividend (yen)	70		70		

Estimated exchange rates for 1H FY2010: U.S.\$ = 90 yen, Euro = 125 yen, GBP = 145 yen

Forecast for FY2010 Consolidate Financial Results (no change from the disclosure in May 2010)



(Billion Yen, %)

	FY2009		FY2010		
	Results	%	Forecast	%	YOY
Net Sales	803.2	100.0	810.0	100.0	101
Cost of Sales	160.7	20.0	169.0	20.9	105
Gross Profit	642.4	80.0	641.0	79.1	100
R&D Expenses	179.1	22.3	157.0	19.4	88
SG&A Expenses	376.9	46.9	379.0	46.8	101
Operating Income	86.4	10.8	105.0	13.0	122
Ordinary Income	79.7	9.9	98.5	12.2	124
Net Income	40.3	5.0	65.0	8.0	161
EPS (yen)	141.6		228.1		
Cash Income	126.4		120.0		
Dividend (yen)	150		150		

Estimated exchange rates for FY2010: U.S. \$ = 90 yen, Euro = 125 yen, GBP = 145 yen

FY2009 consolidated financial results include in-process R&D of 23.9 billion yen from the acquisition of AkaRx, Inc.



Performance of U.S. Pharmaceuticals Business



(US MM\$, %)

		April - June 2009		April - June 2010		
		Results	%	Results	%	YOY
Net Sales		853	100.0	963	100.0	113
Aricept		438	51.4	545	56.7	124
AcipHex		203	23.8	185	19.2	91
	Aloxi	97		96		99
	Dacogen	43		47		110
	Total MGI	151		152		101
	Fragmin	33		47		144
Total oncology-related products		199	23.3	216	22.4	108
Segment Profit		227	26.7	288	29.9	127

Segment profit from U.S. pharmaceuticals business in local currency was calculated based on average exchange rate

Performance of Europe Pharmaceuticals Business



(Billion Yen, %)

	April - June 2009		April - June 2010		
	Results	%	Results	%	YOY
Net Sales	12.4	100.0	11.1	100.0	90[101]
Aricept	7.2	58.0	5.8	51.9	81 [91]
Pariet	2.1	16.9	1.8	16.3	88 [98]
Zonegran	1.0	8.0	1.1	9.7	108 [120]
Segment Profit	2.0	16.2	1.3	11.5	64

[] based on local currency



	April - June 2009		April - June 2010		
	Results	%	Results	%	YOY
Net Sales	7.5	100.0	8.8	100.0	117[119]
Methycobal	1.8	24.8	2.3	26.1	124[130]
Aricept	1.6	20.9	1.7	19.1	108[106]
Pariet	1.4	18.8	1.3	15.1	94 [94]
HUMIRA	0.5	6.2	0.8	9.6	183[181]
Stronger Neo-Mi					